1. Home
  2. NXGL vs SILO Comparison

NXGL vs SILO Comparison

Compare NXGL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.17

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$1.47

Market Cap

3.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
SILO
Founded
1997
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.1M
IPO Year
2019
2011

Fundamental Metrics

Financial Performance
Metric
NXGL
SILO
Price
$0.17
$1.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 281.0K
46.1K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
24.00
★ 57.98
EPS
★ N/A
N/A
Revenue
★ $11,421,000.00
$72,102.00
Revenue This Year
$38.23
N/A
Revenue Next Year
$53.72
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 31.46
N/A
52 Week Low
$0.16
$0.22
52 Week High
$2.89
$7.95

Technical Indicators

Market Signals
Indicator
NXGL
SILO
Relative Strength Index (RSI) 27.36 18.64
Support Level $0.16 $0.30
Resistance Level $0.59 $4.80
Average True Range (ATR) 0.03 0.15
MACD -0.00 0.03
Stochastic Oscillator 13.77 20.11

Price Performance

Historical Comparison
NXGL
SILO

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: